SAN DIEGO, Nov. 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D., is scheduled to present a corporate overview at the following 2014 healthcare conferences: the Stifel 2014 Healthcare Conference and the Canaccord Genuity Medical Technologies and Diagnostics Forum. Each presentation will be webcast, and replays of each will be available at www.trovagene.com and archived for 90 days.
Stifel 2014 Healthcare Conference
Trovagene is scheduled to present at the Stifel 2014 Healthcare Conference, taking place at The New York Palace Hotel, New York, on Wednesday, November 19, at 10:20 a.m. EST. The presentation will be webcast live at http://www.veracast.com/webcasts/stifel/healthcare2014/39205522246.cfm and can also be accessed through the investor relations page at www.trovagene.com.
Canaccord Genuity Medical Technologies and Diagnostics Forum
Trovagene is scheduled to present at the Canaccord Genuity Medical Technologies and Diagnostics Forum 2014 at the Westin Grand Central in New York, on Thursday, November 20, at 2:00 p.m. EST. The presentation will be webcast live at http://www.wsw.com/webcast/canaccord16 and can also be accessed through the investor relations page at www.trovagene.com.
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.
SOURCE Trovagene, Inc.